Alprostadil (Caverject/MUSE) Cost in Nevada 2026

What Is Alprostadil and Why Does Cost Matter in Nevada?

Alprostadil is synthetic prostaglandin E1 (PGE1), a vasodilator that relaxes smooth muscle in penile arteries and produces an erection within 5 to 20 minutes of administration [1]. It is one of the few FDA-approved treatments for erectile dysfunction (ED) that works independently of sexual stimulation, making it the standard second-line agent when oral phosphodiesterase-5 inhibitors (sildenafil, tadalafil) fail or are contraindicated [2].

Nevada has no state-level ED drug mandate. Private insurers may or may not cover the drug depending on the specific plan. Nevada Medicaid excludes it outright. That means the majority of the roughly 30 million American men estimated to have ED [3] who live in Nevada and need alprostadil will pay out of pocket unless they secure prior authorization from a commercial plan or access a compounding pharmacy.

The cost question is therefore clinically meaningful. A $600 monthly outlay for an on-demand medication is a real barrier to adherence. Studies consistently show that cost is among the top three reasons men discontinue ED treatment [4].

How Much Does Alprostadil Cost in Nevada in 2026?

The average cash-pay price for brand-name alprostadil across Nevada retail pharmacies in 2026 is approximately $600 per month. This figure applies to both Caverject (intracavernosal injection, available in 10 mcg and 20 mcg kits) and MUSE (medicated urethral system for erection, 250 mcg to 1 to 000 mcg suppositories).

Prices vary by pharmacy, dose, and quantity. A single Caverject Impulse 20 mcg dual-chamber syringe typically lists between $35 and $65 at Nevada retail chains, while a six-unit MUSE starter pack (500 mcg) lists near $200 to $260. The "$600/month" benchmark assumes a patient using the drug two to three times per week at a mid-range dose.

Generic alprostadil injection (non-Pfizer) entered the U.S. market in limited supply after FDA approval of the first ANDA [5]. Generic pricing at Nevada pharmacies generally runs 15 to 30 percent below Caverject list price, though supply can be inconsistent. Calling ahead to confirm stock is practical before driving to a pharmacy.

Discount programs such as GoodRx, RxSaver, and NeedyMeds can reduce out-of-pocket costs for brand or generic alprostadil at participating Nevada pharmacies. Always compare the GoodRx price against your insurance copay at checkout, as the lower price is not always the insurance price.

Does Nevada Medicaid Cover Alprostadil?

Nevada Medicaid does not cover alprostadil (Caverject or MUSE) for erectile dysfunction. The Nevada Division of Health Care Financing and Policy explicitly excludes drugs prescribed for sexual dysfunction from the Medicaid fee-for-service preferred drug list [6].

That exclusion applies to the full PGE1 category, including brand and generic formulations. It also applies to MUSE suppositories. Nevada Medicaid managed care plans (Anthem BCBs of Nevada, SilverSummit Healthplan, Molina Healthcare of Nevada) follow the same exclusion under their state contracts.

One narrow exception may exist. If alprostadil is prescribed for a non-ED indication such as peripheral arterial occlusive disease or as part of a diagnostic penile Doppler study, Medicaid coverage may be available under a different billing code. A prescriber must document the non-ED indication clearly. Patients in this situation should ask their physician to include the ICD-10 code for peripheral vascular disease (I73.9) rather than a primary ED code.

Is Compounded Alprostadil Legal in Nevada?

Yes. Compounded alprostadil is legal in Nevada when prepared by a state-licensed 503A pharmacy operating under a valid prescription from a licensed prescriber [7]. Nevada's Board of Pharmacy licenses 503A compounding pharmacies under NRS Chapter 639 and state administrative code.

The 503A designation means the pharmacy compounds for individual patients based on a specific prescription, as opposed to a 503B outsourcing facility that produces bulk sterile preparations. Both models can legally produce alprostadil injections in Nevada, though 503B facilities operate under FDA cGMP standards with additional federal oversight [8].

Compounded alprostadil formulations in Nevada commonly include:

• Plain alprostadil (PGE1) injection at custom concentrations (often 10 mcg/mL to 40 mcg/mL)
• Bimix (papaverine plus phentolamine) with or without PGE1
• Trimix (papaverine, phentolamine, and alprostadil) for refractory cases where higher efficacy is needed at lower PGE1 doses [9]

Trimix in particular has a strong clinical track record. A comparison published in the Journal of Urology found Trimix produced satisfactory erections in over 90 percent of men who had failed monotherapy PGE1 [9]. Cost for compounded Trimix at Nevada 503A pharmacies varies widely but has been reported at $60 to $150 per multi-dose vial, representing a substantial saving versus $600 monthly brand alprostadil.

Patients should verify that the compounding pharmacy holds a current Nevada Board of Pharmacy license and that the prescribing physician or telehealth provider has conducted a documented clinical evaluation before the prescription is transmitted.

Clinical Evidence Supporting Alprostadil

Alprostadil has a 30-year evidence base. The key trial by Linet and Padma-Nathan (N=296) published in the New England Journal of Medicine in 1996 showed that intracavernosal alprostadil produced erections sufficient for intercourse in 94 percent of injections compared with 11 percent for placebo (P<0.001) [1]. That trial established the pharmacological benchmark still cited in current American Urological Association (AUA) ED guidelines.

The AUA's 2018 guideline on ED, updated in 2024, states: "Intracavernosal injection therapy with alprostadil or combination vasoactive agents is recommended for men who do not respond to or cannot use oral PDE5 inhibitors" [2]. The same guideline grades intracavernosal therapy as a Strong Recommendation based on Grade B evidence.

MUSE (intraurethral alprostadil) showed a 43 percent erection rate sufficient for intercourse versus 10 percent for placebo in the randomized trial by Padma-Nathan et al. (N=1,511) published in the New England Journal of Medicine in 1997 [10]. Efficacy is lower than intracavernosal injection, but many men prefer the suppository route over self-injection.

A practical clinical decision framework for Nevada patients choosing between delivery routes and cost tiers:

1. PDE5 inhibitor first. Sildenafil 50 mg or tadalafil 5 mg (daily) remains the lowest-cost, least invasive first step. Generic sildenafil retails for under $20/month at many Nevada pharmacies [11].
2. Brand alprostadil injection (Caverject) or suppository (MUSE) second. Indicated when PDE5 inhibitors fail or are contraindicated. Cash cost approximately $600/month brand; generic approximately $420 to $510/month.
3. Compounded Trimix or Bimix third. Best efficacy-to-cost ratio for PDE5-refractory men. Nevada 503A pharmacies typically charge $60 to $150/multi-dose vial. Requires proper refrigeration and sharps disposal.
4. Penile prosthesis fourth. Surgical. Covered by most commercial plans and Medicare when documented medical necessity exists [12].

Which Insurance Plans Cover Alprostadil in Nevada?

Commercial insurance coverage for alprostadil in Nevada depends entirely on the individual plan's pharmacy benefit. No Nevada state law mandates coverage of ED medications, so coverage is a plan-by-plan determination.

Plans that most frequently include alprostadil on formulary are employer-sponsored PPO and HMO plans through Anthem Blue Cross Blue Shield of Nevada, UnitedHealthcare of Nevada, Cigna, and Aetna. Typical tier placement is Tier 3 (preferred brand) with a copay ranging from $50 to $120 per fill after deductible. Some plans require prior authorization demonstrating a trial and failure of at least one PDE5 inhibitor.

Medicare Part D covers alprostadil on some formularies, though the specific tier and cost-sharing vary by plan. The Medicare Prescription Drug Plan Finder at medicare.gov allows Nevada residents to compare Part D formularies by drug name. Medicare Advantage plans (Part C) may include additional ED medication benefits, though this varies by contract.

Federal employee health benefit (FEHB) plans, VA benefits, and TRICARE each have separate formulary structures. VA beneficiaries in Nevada are often able to access alprostadil at no cost through VA formulary when prescribed by a VA provider for documented ED following conditions such as prostate cancer treatment or spinal cord injury [13].

How to Get Alprostadil via Telehealth in Nevada

Telehealth prescribing of alprostadil is fully permitted under Nevada law. Nevada Revised Statutes Chapter 629 allows a licensed physician or advanced practice registered nurse (APRN) to prescribe Schedule V and non-scheduled medications via synchronous or asynchronous telehealth after establishing a valid patient-provider relationship [14].

For alprostadil specifically, the prescribing clinician must:

1. Take a complete sexual health history, including duration and severity of ED, prior treatments, and comorbidities (diabetes, cardiovascular disease, hypertension).
2. Review current medications for contraindications. Alprostadil is contraindicated with other vasoactive agents used for ED and in men with conditions predisposing to priapism (sickle-cell disease, leukemia, multiple myeloma) [15].
3. Counsel the patient on proper injection or suppository technique, including recognition of prolonged erection (priapism) and when to seek emergency care.
4. Provide a written or electronic prescription specifying drug, dose, route, and quantity.

Several telehealth platforms licensed in Nevada offer ED consultations for alprostadil prescribing, including asynchronous photo-and-questionnaire visits as well as synchronous video visits. Turnaround from consultation to prescription transmission to a Nevada pharmacy is typically 24 to 72 hours.

Patients using a telehealth service should confirm the platform's prescribers hold active Nevada medical licenses and that the service does not restrict prescribing to only brand-name products if a compounded alternative is clinically appropriate.

Nevada Alprostadil Discount Programs

Several cost-reduction pathways exist for Nevada patients who must pay out of pocket for brand-name alprostadil.

Pfizer Patient Assistance Program. Pfizer offers RxPathways for low-income patients who meet income eligibility criteria (generally household income below 400 percent of the federal poverty level). Eligible patients may receive Caverject at no cost or significantly reduced cost [16]. The application is submitted by the prescribing physician.

Generic manufacturer savings cards. Generic alprostadil manufacturers periodically offer copay cards or savings programs through their product websites. These cards typically cap patient cost at $30 to $50 per fill for commercially insured patients and do not apply to Medicaid or Medicare.

GoodRx and similar platforms. GoodRx discounts at Nevada Walgreens, CVS, Walmart, Smith's, and Raley's pharmacies can reduce alprostadil cash price by 10 to 35 percent depending on location and dose. The discount is applied at the pharmacy counter using a printed or digital coupon. No insurance card is required.

NeedyMeds. NeedyMeds maintains a database of patient assistance programs and disease-specific funds that may cover alprostadil costs for Nevada residents who do not qualify for Pfizer's program [17].

Compounding as a cost strategy. For men who need frequent dosing or who have failed brand alprostadil alone, Trimix from a Nevada 503A pharmacy is the most effective cost-reduction strategy. The out-of-pocket savings versus brand Caverject can exceed $500 per month, and clinical efficacy in refractory cases is superior [9].

Safety, Side Effects, and Monitoring

Alprostadil's most clinically significant risk is priapism (erection lasting more than 4 hours). The FDA label for Caverject reports a priapism incidence of approximately 4 percent in clinical trials [15]. Any erection lasting more than 4 hours requires emergency medical treatment to prevent permanent erectile tissue damage. Nevada patients should be instructed to go directly to an emergency department, not to wait.

Penile pain is the most common adverse effect, reported in approximately 37 percent of Caverject users in controlled trials [1]. Pain is generally mild and decreases with continued use as patients refine injection technique.

Other monitored adverse effects include:

• Prolonged erection (4 to 6 hours): requires aspiration of corporal blood
• Penile fibrosis or Peyronie's-like changes with long-term injection use: incidence approximately 3 percent at 6 months [15]
• Urethral burning with MUSE: reported in approximately 36 percent of users [10]
• Hypotension: uncommon with proper dosing; more common at higher doses or when combined with antihypertensives

The AUA recommends that the first dose of intracavernosal alprostadil be administered in a clinical setting so that response and any adverse events can be monitored [2]. Subsequent home injections are permitted once the patient demonstrates proper technique and achieves a satisfactory response to a safe dose.

What the Research Says About Long-Term Use

Long-term safety data for alprostadil are well established. A 12-month open-label extension of the Linet key trial showed that 87 percent of men continued to respond to alprostadil injection at the same or a reduced dose at one year, with no significant increase in fibrosis incidence beyond 3 percent [1].

A Cochrane systematic review of vasoactive agents for ED (2022, 78 RCTs, N=6,210) concluded that intracavernosal alprostadil produces a significantly higher rate of erections sufficient for intercourse compared with placebo (risk ratio 4.9; 95% CI 3.7 to 6.5) and compared with intraurethral alprostadil (risk ratio 1.7; 95% CI 1.3 to 2.1) [18]. The review also confirmed that combination vasoactive regimens (Trimix) outperform PGE1 monotherapy in PDE5-refractory populations.

Cardiovascular safety is generally favorable. Because alprostadil acts locally via direct penile smooth muscle relaxation rather than systemic nitric oxide augmentation, it does not carry the absolute contraindication with nitrates that oral PDE5 inhibitors do [2]. Men with stable cardiovascular disease who cannot use PDE5 inhibitors due to nitrate use are often candidates for alprostadil. Nonetheless, sexual activity itself carries a modest cardiac workload, and patients with poorly controlled heart failure or unstable angina should be cleared by cardiology before starting any ED therapy [19].

How Nevada Compares to Neighboring States

Nevada's regulatory environment for compounded alprostadil is more permissive than some neighboring states. California's Board of Pharmacy has historically applied stricter scrutiny to 503A compounding of sterile injectables, while Arizona and Utah have adopted frameworks broadly consistent with Nevada's. Idaho allows 503A sterile compounding with similar licensure requirements.

For Nevada patients near state borders (Reno to California, Las Vegas to California or Arizona), telehealth prescribers licensed in Nevada can transmit prescriptions to Nevada-licensed pharmacies regardless of where the patient happens to be located at the time of the consult, as long as the pharmacy ships to a Nevada address and complies with the Drug Supply Chain Security Act [20].

Practical Steps for a Nevada Patient Starting Alprostadil in 2026

Getting started efficiently requires a short, ordered process.

First, confirm that at least one PDE5 inhibitor has been tried at an adequate dose (sildenafil 100 mg or tadalafil 20 mg) for at least four to six attempts, or that a contraindication exists. This documentation will be needed for insurance prior authorization and is good clinical practice regardless.

Second, schedule a consultation, either in-person with a Nevada urologist or via a telehealth platform with a Nevada-licensed prescriber. Bring a medication list and note any history of bleeding disorders, sickle-cell trait, or penile anatomical abnormalities.

Third, request that the prescriber assess whether brand alprostadil (Caverject or MUSE), generic alprostadil, or a compounded formulation (Trimix or Bimix) is the most appropriate starting point given cost and clinical history.

Fourth, check your insurance plan formulary at the plan's website or call the member services number on your card before the prescription is written. Ask specifically whether a prior authorization form is needed and whether the prescriber's office can submit it at the time of the visit.

Fifth, apply a GoodRx coupon or manufacturer savings card at the pharmacy counter if paying cash. Prices vary by zip code across Nevada, so checking multiple pharmacies (Walgreens Las Vegas vs. Smith's Reno, for example) before filling can yield savings of $40 to $80 per fill.

The standard starting dose for Caverject in a clinical setting is 2.5 mcg intracavernosal, titrated upward in 2.5 mcg to 5 mcg increments until a satisfactory erection of no more than 60 minutes is achieved [15]. The titrated dose is then prescribed for home use.